Whole-Genome Sequencing of Pharmacogenetic Drug Response in Racially Diverse Children with Asthma
Albuterol, a bronchodilator medication, is the first-line therapy for asthma worldwide. There are significant racial/ethnic differences in albuterol drug response. To identify genetic variants important for bronchodilator drug response (BDR) in racially diverse children. We performed the first whole...
Saved in:
Published in | American journal of respiratory and critical care medicine Vol. 197; no. 12; pp. 1552 - 1564 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
American Thoracic Society
15.06.2018
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Albuterol, a bronchodilator medication, is the first-line therapy for asthma worldwide. There are significant racial/ethnic differences in albuterol drug response.
To identify genetic variants important for bronchodilator drug response (BDR) in racially diverse children.
We performed the first whole-genome sequencing pharmacogenetics study from 1,441 children with asthma from the tails of the BDR distribution to identify genetic association with BDR.
We identified population-specific and shared genetic variants associated with BDR, including genome-wide significant (P < 3.53 × 10
) and suggestive (P < 7.06 × 10
) loci near genes previously associated with lung capacity (DNAH5), immunity (NFKB1 and PLCB1), and β-adrenergic signaling (ADAMTS3 and COX18). Functional analyses of the BDR-associated SNP in NFKB1 revealed potential regulatory function in bronchial smooth muscle cells. The SNP is also an expression quantitative trait locus for a neighboring gene, SLC39A8. The lack of other asthma study populations with BDR and whole-genome sequencing data on minority children makes it impossible to perform replication of our rare variant associations. Minority underrepresentation also poses significant challenges to identify age-matched and population-matched cohorts of sufficient sample size for replication of our common variant findings.
The lack of minority data, despite a collaboration of eight universities and 13 individual laboratories, highlights the urgent need for a dedicated national effort to prioritize diversity in research. Our study expands the understanding of pharmacogenetic analyses in racially/ethnically diverse populations and advances the foundation for precision medicine in at-risk and understudied minority populations. |
---|---|
Bibliography: | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 Current affiliation: Genentech, South San Francisco, California. These authors contributed equally to this work. Current affiliation: Allergy and ENT Associates, The Woodlands, Texas. Current affiliation: The Scripps Research Institute, La Jolla, California. Current affiliation: Division of Biostatistics, Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis, Tennessee. |
ISSN: | 1073-449X 1535-4970 |
DOI: | 10.1164/rccm.201712-2529OC |